These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 27644029)

  • 21. Finasteride for androgenetic alopecia is not associated with sexual dysfunction: a survey-based, single-centre, controlled study.
    Haber RS; Gupta AK; Epstein E; Carviel JL; Foley KA
    J Eur Acad Dermatol Venereol; 2019 Jul; 33(7):1393-1397. PubMed ID: 30835851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sexual Problems of Men With Androgenic Alopecia Treated With 5-Alpha Reductase Inhibitors.
    Coskuner ER; Ozkan B; Culha MG
    Sex Med Rev; 2019 Apr; 7(2):277-282. PubMed ID: 30301703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An observational retrospective evaluation of 79 young men with long-term adverse effects after use of finasteride against androgenetic alopecia.
    Chiriacò G; Cauci S; Mazzon G; Trombetta C
    Andrology; 2016 Mar; 4(2):245-50. PubMed ID: 26763726
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 5α-Reductase inhibitors in men aged 50 years or older with androgenetic alopecia: A retrospective study.
    Kang MJ; Choi JY; Sim WY; Lew BL
    J Am Acad Dermatol; 2021 Jan; 84(1):172-173. PubMed ID: 32320771
    [No Abstract]   [Full Text] [Related]  

  • 25. Post-finasteride syndrome: a surmountable challenge for clinicians.
    Traish AM
    Fertil Steril; 2020 Jan; 113(1):21-50. PubMed ID: 32033719
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate, baldness drugs linked to sexual dysfunction.
    Kuehn BM
    JAMA; 2012 May; 307(18):1903. PubMed ID: 22570451
    [No Abstract]   [Full Text] [Related]  

  • 27. A Review of the FAERS Data on 5-Alpha Reductase Inhibitors: Implications for Postfinasteride Syndrome.
    Baas WR; Butcher MJ; Lwin A; Holland B; Herberts M; Clemons J; Delfino K; Althof S; Kohler TS; McVary KT
    Urology; 2018 Oct; 120():143-149. PubMed ID: 29960004
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Research Brief: Self-Reports of a Constellation of Persistent Antiandrogenic, Estrogenic, Physical, and Psychological Effects of Finasteride Usage Among Men.
    Walf AA; Kaurejo S; Frye CA
    Am J Mens Health; 2018 Jul; 12(4):900-906. PubMed ID: 29318957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alterations of gut microbiota composition in post-finasteride patients: a pilot study.
    Borgo F; Macandog AD; Diviccaro S; Falvo E; Giatti S; Cavaletti G; Melcangi RC
    J Endocrinol Invest; 2021 Jun; 44(6):1263-1273. PubMed ID: 32951160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 5α-Reductase inhibitors in androgenetic alopecia.
    Yim E; Nole KL; Tosti A
    Curr Opin Endocrinol Diabetes Obes; 2014 Dec; 21(6):493-8. PubMed ID: 25268732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Finasteride and Its Potential for the Treatment of Female Pattern Hair Loss: Evidence to Date.
    Iamsumang W; Leerunyakul K; Suchonwanit P
    Drug Des Devel Ther; 2020; 14():951-959. PubMed ID: 32184564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral Finasteride Presents With Sexual-Unrelated Withdrawal in Long-Term Treated Androgenic Alopecia in Men.
    Perez-Mora N; Velasco C; Bermüdez F
    Skinmed; 2015; 13(3):179-83. PubMed ID: 26380503
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Post-finasteride syndrome.
    Pereira AFJR; Coelho TOA
    An Bras Dermatol; 2020; 95(3):271-277. PubMed ID: 32317131
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comments concerning the real risk of sexual adverse events secondary to the use of 5-ARIs.
    Pirozzi Farina F; Pischedda A
    Arch Ital Urol Androl; 2016 Jan; 87(4):312-6. PubMed ID: 26766804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of sexual function in subjects taking finasteride for the treatment of androgenetic alopecia.
    Tosti A; Piraccini BM; Soli M
    J Eur Acad Dermatol Venereol; 2001 Sep; 15(5):418-21. PubMed ID: 11763381
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Are hand preference and sexual orientation possible predicting factors for finasteride adverse effects in male androgenic alopecia?
    Motofei IG; Rowland DL; Georgescu SR; Tampa M; Baleanu BC; Paunica S
    Exp Dermatol; 2016 Jul; 25(7):557-8. PubMed ID: 26990657
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical efficacy of oral administration of finasteride at a dose of 2.5 mg/day in women with female pattern hair loss.
    Won YY; Lew BL; Sim WY
    Dermatol Ther; 2018 Mar; 31(2):e12588. PubMed ID: 29464847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Finasteride for hair loss: a review.
    Gupta AK; Venkataraman M; Talukder M; Bamimore MA
    J Dermatolog Treat; 2022 Jun; 33(4):1938-1946. PubMed ID: 34291720
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of sexual function with an international index of erectile function in subjects taking finasteride for androgenetic alopecia.
    Tosti A; Pazzaglia M; Soli M; Rossi A; Rebora A; Atzori L; Barbareschi M; Benci M; Voudouris S; Vena GA
    Arch Dermatol; 2004 Jul; 140(7):857-8. PubMed ID: 15262698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessing finasteride-associated sexual dysfunction using the FAERS database.
    Gupta AK; Carviel J; MacLeod MA; Shear N
    J Eur Acad Dermatol Venereol; 2017 Jun; 31(6):1069-1075. PubMed ID: 28300347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.